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Brief communicationIdentification of fatty acid binding protein 4 as
an adipokine that regulates insulin secretion
during obesityLindsay E. Wu 1,2, Dorit Samocha-Bonet 1,2, P. Tess Whitworth 1, Daniel J. Fazakerley 1, Nigel Turner 1,2,
Trevor J. Biden 1,3, David E. James 1,4,**, James Cantley 1,3,5,*ABSTRACT
A critical feature of obesity is enhanced insulin secretion from pancreatic b-cells, enabling the majority of individuals to maintain glycaemic
control despite adiposity and insulin resistance. Surprisingly, the factors coordinating this adaptive b-cell response with adiposity have not been
delineated. Here we show that fatty acid binding protein 4 (FABP4/aP2) is an adipokine released from adipocytes under obesogenic conditions,
such as hypoxia, to augment insulin secretion. The insulinotropic action of FABP4 was identified using an in vitro system that recapitulates
adipocyte to b-cell endocrine signalling, with glucose-stimulated insulin secretion (GSIS) as a functional readout, coupled with quantitative
proteomics. Exogenous FABP4 potentiated GSIS in vitro and in vivo, and circulating FABP4 levels correlated with GSIS in humans. Insulin
inhibited FABP4 release from adipocytes in vitro, in mice and in humans, consistent with feedback regulation. These data suggest that FABP4
and insulin form an endocrine loop coordinating the b-cell response to obesity.
 2014 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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The current global obesity epidemic is associated with a cluster of
diseases including type 2 diabetes (T2D) [1,2], cardiovascular disease
[3,4] and cancer [5,6]. Obesity is often accompanied by insulin
resistance and enhanced insulin secretion from pancreatic b-cells
[7,8]. If GSIS remains tightly coupled to insulin resistance, normal
glycaemic control is maintained. In contrast, failure of GSIS to
compensate for insulin resistance leads to hyperglycaemia and in
some cases T2D [9]. The molecular mechanisms that coordinate
enhanced GSIS with increased adiposity to maintain glycaemic control
in the pre-diabetic state are not understood.
Blood glucose, although a major determinant of insulin secretion,
appears largely uncoupled from the pronounced enhancement of in-
sulin secretion in obese mice [10] and humans [8] that display blood
glucose levels within the normal range. Non-esterified fatty acids
(NEFAs) potentiate GSIS [11], yet increases in adiposity often occur
independently from changes in plasma NEFA [12] suggesting that
NEFA are not a common driver of compensatory insulin secretion.
Adipokines regulate b-cell function, however the two most well
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with adiposity [13], inhibits insulin release [14] while adiponectin, a
potentiator of GSIS [15,16], decreases with obesity [17]. The adipose
enriched, secreted enzyme eNampt/visfatin augments GSIS in mice
[18], although only subtle alterations in serum concentrations
accompany obesity and correlate negatively with insulin secretion in
humans [19]. In the current study, we sought to address the hypothesis
that another adipokine plays an integral role coupling b-cell function
with adiposity, thereby facilitating enhanced insulin secretion during
obesity.
2. MATERIALS AND METHODS
2.1. Cell culture and islet isolation
Cell culture reagents were from Life Technologies unless otherwise
indicated. 3T3-L1 fibroblasts were differentiated into adipocytes as
described [20] and used for experiments 8 days post-differentiation.
For signalling experiments, 3T3-L1 adipocytes were stimulated with
b-3 adrenergic agonists CL316243 and BRL37344 (Sigma) at 0.1 mg/
ml in PBS, or 3-Isobutyl-1-methylxanthine (IBMX; Sigma) at 500 mmol/l
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Brief communicationPBS. Islet isolation, culture and insulin secretion experiments were
performed as described [21].
2.2. Conditioned media experiments
We conditioned serum-free islet media (RPMI1640 containing penicillin,
streptomycin and L-glutamine) by culturing with 3T3-L1 adipocytes for
18 hours under normoxic (21%O2, 5% CO2, 74%N2) or hypoxic (1%O2,
5% CO2, 94% N2) atmospheres, followed by 0.45 mm filtration to
remove detached cells. From this conditioned media, a >10 kDa
protein fraction was dialysed against fresh islet media using centrifugal
filtration (Amicon/Merck Millipore), then reconstituted at a 3 con-
centration (i.e. 33% of starting volume of conditioned media) in fresh
islet media containing 10% foetal calf serum, before being used to
culture isolated mouse islets for 24 h. Insulin secretion was subse-
quently assessed for 1 h. Replicate insulin secretion data were aver-
aged to give a single data point (n) for each batch of conditioned media.
2.3. Proteomics
Stable-isotope labelling by amino acids in cell culture (SILAC) [22]
labelling of 3T3-L1 fibroblasts was performed as described [23], us-
ing “heavy” amino acid isotopes arginine U-13C6 U-
15N4 (CNLM-539)
and lysine U-13C6 U-
15N2 (CNLM-291) from Cambridge Isotope Labo-
ratories, and non-labelled “light” equivalents from Sigma. To reduce
amino acid conversion to proline [24], arginine was used at 0.021 g/L,
and lysine at 0.0365 g/L. Differentiated labelled 3T3-L1 adipocytes
were used to condition media, with “light” cells cultured under nor-
moxia and “heavy” cells under hypoxia. Conditioned media were
collected and mixed in a 1:1 ratio to reduce subsequent inter-sample
handling variability. Secreted proteins were enriched, precipitated,
resolved by SDS-PAGE and subjected to in-gel trypsin digestion, as
described [25]. Resulting peptides were subjected to liquid chroma-
tography and tandem mass spectrometry using a Waters Ultima in-
strument at the Bioanalytical Mass Spectrometry Facility at the
University of New South Wales. Data were analysed using Mascot
Distiller v2.3.1.0. The SwissProt reference database was queried using
Mascot Server 2.2 to identify peptide spectra. Only proteins repre-
sented by >5 unique peptide spectra were retained for further anal-
ysis. Potential for secretion was predicted using SecretomeP2.0 [26].
2.4. Recombinant FABP4 production
Recombinant FABP4 (rFABP4) used in Figure 2A and B was from
Cayman Chemicals. rFABP4 used in all other figures was produced as
follows. Mouse Fabp4 (GenBank BC054426.1) was cloned into His-tag
expression vector pDEST17, transformed into BL21 Escherichia coli,
and 0.5 ocular density cultures induced to produce rFABP4 by 1 mmol/l
IPTG treatment. After 6 h, cultures were DNAseI and lysozyme treated,
before addition of 1% Triton X-100. Clarified lysates were applied to
Co2þ coated agarose bead columns and washed. For in vivo rFABP4e
linoleate experiments, 0.4 mmol/l linoleate was passed over the col-
umn, followed by washing, to enable coupling with rFABP4. rFABP4
was eluted with 300 mmol/l imidazole and dialysed against PBS. Size,
identity and purity of rFABP4 were confirmed by SDS-PAGE with
Western blotting and Coomassie blue (Sigma) protein staining
(Figure S1A and B). Our rFABP4 preparations contain very low endo-
toxin levels <0.02 EU/mg protein (Lonza LAL assay).
2.5. Preparation of fatty acids
Linoleate (Nu-Chek prep) was stored at 80 C under nitrogen.
Immediately before use, 0.4 mmol/l linoleate or sodium-palmitate
(Sigma) were solubilised by coupling to 0.92% BSA (Sigma).466 MOLECULAR METABOLISM 3 (2014) 465e473  2014 Published by Elsevier GmbH2.6. Mouse studies
2.6.1. Welfare
12-week old C57Bl/6J mice were purchased from Australian Bio-
Resources and housed in groups of 2e5, within a barrier facility with
12 h light/dark cycles. Environmental enrichment was provided and
mice had free access to a standard lab diet [27] and water. Approval
for mouse studies was issued to J.Cantley by the Garvan Institute/
St.Vincent’s Hospital Animal Ethics Committee.
2.6.2. Diet-induced obesity
10-week old male mice were fed either a standard lab diet (lean) or
high-fat diet (obese) for 40 weeks. Diet composition was described
previously [27].
2.6.3. rFABP4 treatment
Mice were treated with rFABP4elinoleate via i.p. injection (80 mg) or
by subcutaneous implantation of osmotic mini-pumps (Alzet)
providing a 0.5 ml/h flow rate and mean rFABP4 dose of 1.22 mg/h.
Mini-pumps were loaded, primed and implanted (mid-scapular) into
mice under gaseous general anaesthesia (1e4% isoflurane in oxy-
gen), with ketoprofen (5 mg/kg) and marcaine (8 mg/kg) used as local
analgesics.
2.6.4. Metabolic testing
Glucose tolerance testing (GTT) was performed after a 6 h fast (with
free access to water), by intraperitoneal (i.p.) injection of sterile 20%
glucose (2 g/kg). Insulin action was assessed by i.p. injection of insulin
(0.75 U/kg) following a 6 h fast. Blood was obtained from the tail tip for
glucose monitoring (Roche Accu-Chek Performa glucometer) and in-
sulin assay (Crystal Chem ELISA). Circulating FABP4 was assayed by
ELISA (Circulex/MBL).2.7. Human studies
2.7.1. Participants
Sedentary, non-diabetic Caucasian participants were recruited
(n ¼ 17, 4 males). Mean age and body mass index (BMI)  standard
error (SEM) were 56  2 years and 26  1 kg/m2, respectively.
Exclusion criteria were: weight instability (>2 kg change in the pre-
ceding 6 months), exercising more than 60 min per week, taking
medications known to affect glucose homeostasis, or a personal his-
tory of type 2 diabetes or cardiovascular disease. The study protocol
was approved by the Human Research and Ethics Committee at St
Vincent’s Hospital, Sydney. Participants provided informed written
consent before commencement.
2.7.2. Metabolic testing
Participants attended the Clinical Research Facility at 8 am after a
12-h fast. Weight, height and blood pressure were measured and
fasting blood samples drawn. Glucose tolerance testing (0.3 g/kg
intravenous glucose dose; max 25 g) was performed, followed by a
2-h hyperinsulinaemic (60 mU/m2/min)eeuglycemic (5.0 mmol/L)
clamp. Human serum FABP4 levels were determined by ELISA (Bio-
vendor) and insulin levels determined by RIA (Merck Millipore).
2.7.3. Body composition
Fat mass and fat-free mass were assessed by dual energy X-ray
absorptiometry (DXA; Lunar DPX-Lunar Radiation, GE Healthcare).. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2.8. Western blotting
Cell lysates were prepared in RIPA buffer and western blotting per-
formed as described [21] using 12% polyacrylamide gels. Extracellular
released proteins were detected by western blotting proteins from
equal volumes of filtered conditioned media. Antibodies used were:
FABP4 (Cell Signaling Technology), FABP5 (gift from Prof. Charles
Mackay), Adiponectin (Merck Millipore or Sigma), complement C3 (MP
Biomedicals), 14-3-3b (Santa Cruz Biotechnology).
2.9. Statistical analysis
All data are reported as mean SEM. Area under the curves (AUC) and
incremental AUC (iAUC) of blood glucose and serum insulin were
calculated using the trapezoidal method. Differences between groups
were tested using 2-tailed unpaired t-tests or ANOVA with Tukey’s
multiple comparisons test as indicated. Correlation analyses were
carried out using Pearson correlations. Stepwise regression was used
to determine whether adjustment for baseline serum FABP4 and body
fat mass or BMI could explain GSIS. Two-tailed P <0.05 was taken to
be statistically significant. Analyses were performed using SPSS Sta-
tistics 21 (SPSS) and Prism 6 (GraphPad Software) software.
3. RESULTS
3.1. Proteins released from hypoxic adipocytes modulate insulin
secretion
Recent evidence indicates that nutrient excess in humans and mice is
accompanied by a rapid expansion of fat mass that exceeds vascular
capacity leading to transient adipose tissue hypoxia [28e30]. We
reasoned that this scenario might provide an ideal experimental model
system with which to identify insulinotropic adipokines released during
obesity. We established an in vitro culture system, using proteins
recovered from media conditioned by 3T3-L1 adipocytes under nor-
moxic (21% O2) or hypoxic (1% O2) atmospheres, to model adipocyte
to b-cell signalling under lean or obese conditions (Figure 1A). There
was a significant potentiation of GSIS from isolated mouse islets
cultured with proteins released from hypoxic adipocytes, whereas
proteins from normoxic adipocytes did not alter GSIS (Figure 1B). This
indicated that an adipocyte-derived protein(s) enriched in hypoxic
conditioned media modulates b-cell function.
3.2. Adipocyte FABP4 release is enhanced under hypoxic
conditions
To identify proteins enriched in hypoxic 3T3-L1 conditioned media we
utilised SILAC labelling to perform a mass spectrometry-based
quantitative proteomic screen (Supplementary data file 1). From this
screen, we identified 21 proteins that had the potential for secretion
based on gene sequence analysis (Figure 1C and Table S1). Of these
proteins, 4 were enriched in hypoxic 3T3-L1 media thus correlating
with enhanced GSIS in our in vitro system (Figure 1A and B). Sparcl1
and Col6a1 were excluded as they are extracellular matrix proteins.
Enpp2 is a soluble lysophospholipaseD secreted from adipose tissue
[31], however its release was only increased subtly by hypoxia and it is
ubiquitously expressed. The candidate protein that we decided to
pursue was fatty acid binding protein 4 (FABP4/aP2). This FABP is
primarily expressed in adipocytes and macrophages [32] and regulates
whole body glucose metabolism [33], in part via its intracellular role in
adipocyte lipolysis [34,35]. FABP4 is present in the serum of humans,
with levels increasing during obesity [36,37]. Intriguingly, FABP4 has
recently been shown to play a role in the metabolic response to fasting
possibly via a role in FA uptake into muscle [38] as well as in regulating
hepatic glucose production [37]. However, a physiological role forMOLECULAR METABOLISM 3 (2014) 465e473  2014 Published by Elsevier GmbH. This is an open access ar
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Importantly, Fabp4/aP2KO mice display an 80% reduction in circu-
lating insulin levels under high-fat feeding [39], consistent with a role
for circulating FABP4 in modulating b-cell function. FABP4 is therefore
a prime candidate for an insulinotropic adipokine: an adipocyte specific
protein, enriched in both hypoxic-adipocyte conditioned media and in
the serum of obese subjects.
FABP4 release from 3T3L1 adipocytes was confirmed by Western
blotting (Figure 1E), with an 8-fold increase during hypoxia quantified
by ELISA (Figure 1F). In contrast, 3T3L1 adipocyte necrosis increased
only 1.6-fold with hypoxia (Roche cell death detection ELISA, data not
shown). FABP5 was also enriched in hypoxic conditioned media, but
was 5-fold less abundant than FABP4 (Supplementary Data File 1),
indicating that FABP4 is the dominant isoform released from adipo-
cytes. Moreover, the FABP4 protein is restricted to brown and white
adipose tissue, consistent with a potential role as an adipokine,
whereas FABP5 was present in all tissues tested (Figure 1G). We
detected a significant increase in circulating FABP4 in the serum of
mice fed a high-fat diet for 40 weeks to induce obesity, relative to
chow-fed lean control mice (Figure 1H). The physiological range of
circulating FABP4 concentrations in mice (Figure 1H) were similar to
those detected in our 3T3L1 conditioned media experiments
(Figure 1F).
Adiponectin has insulinotropic properties [15,16], however, release of
this adipokine decreased with hypoxia (Figure 1C and D and Table S1),
consistent with reduced adiponectin secretion in obesity [17] and from
hypoxic human adipocytes [40]. Therefore, adiponectin is unlikely to
contribute to enhanced GSIS in our hypoxia conditioned media model
or during obesity in vivo. Leptin is not expressed in 3T3L1 adipocytes
and was not detected in our mass spectrometry experiments.
3.3. FABP4 modulates insulin secretion from b-cells in vitro and
in vivo
To determine if FABP4 can directly potentiate insulin secretion, we
cultured isolated mouse islets with recombinant FABP4 (rFABP4)
in vitro for 24 h, with or without linoleate, a fatty acid that binds FABP4
in a 1:1 ratio and enhances FABP4 activation of nuclear receptors in
adipocytes [41,42], or palmitate, prior to measuring GSIS. rFABP4e
linoleate potentiated GSIS in a dose-dependent manner, whereas
linoleate alone had no effect (Figure 2A). At higher doses, rFABP4
supplied alone potentiated GSIS, with addition of linoleate further
enhancing activity (Figure S1C). Islet insulin content was unaltered
after 24 h rFABP4 treatment (Figure 2B, Figure S1D). We next sought to
test the effects of exogenous FABP4 on GSIS and glucose homeostasis
in vivo by implanting subcutaneous osmotic mini-pumps containing
either PBS or rFABP4elinoleate into mice. rFABP4elinoleate treatment
for 1 week significantly improved glucose tolerance (Figure 2C) with a
moderate enhancement of GSIS (Figure 2D and E), without altering
body weight (Figure 2F). In contrast, acute co-injection of mice with a
supra-physiological bolus of rFABP4elinoleate along with glucose did
not alter glucose tolerance (Figure 2G). These results demonstrate that
FABP4 acts as an insulinotropic adipokine but, unlike the incretin effect
[43], this activity does not occur acutely and manifests over a longer
period.
3.4. Serum FABP4 levels predict the GSIS response in humans
To investigate if the insulinotropic effects of FABP4 could also be
observed in humans, we tested whether circulating FABP4 levels
predict other metabolic parameters in a cohort of non-diabetic humans
with a range of adiposity (BMI 19e36 kg/m2). This cohort demon-
strated tightly regulated glucose tolerance in response to an i.v.ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Figure 1: Identification of FABP4 as a candidate insulinotropic protein released from adipocytes. A, B, Media were conditioned by 18 h culture with 3T3-L1 adipocytes under normoxia (21% O2) or
hypoxia (1% O2), before a >10 kDa protein fraction was purified. Pancreatic islets isolated from mice were cultured for 24 h in media enriched with this conditioned media protein fraction, or
unconditioned media, before insulin secretion were measured for 1 h. n ¼ 9 batches of conditioned media. C, Relative abundance of proteins released from hypoxic vs normoxic 3T3L1 adipocytes,
detected using SILAC labelling and mass spectrometry. D, Fatty acid binding protein 4 (FABP4) and adiponectin spectra. E, Western blots showing increased FABP4 release (extracellular), and stable
intracellular FABP4 levels, during hypoxia; n ¼ 6. F, Quantification of FABP4 release by ELISA; n ¼ 5. G, FABP4 and FABP5 were detected by western blotting protein lysates from a range of mouse
tissues. FABP4 protein was restricted to brown and white adipose tissue. H, Mice were fed a standard lab diet (chow/lean) or high-fat diet (HFD/obese) for 40 weeks. Serum FABP4 concentrations
were significantly increased during obesity. Data presented as mean  SEM. *P < 0.05, ***P < 0.001 by t-test. See also Table S1 and data file S1.
Brief communicationglucose tolerance test but with highly variable GSIS (Figure 3AeC),
providing a spectrum of b-cell compensation. Serum FABP4 was
significantly increased in overweight individuals (BMI >25; Figure 3D)
and correlated positively and significantly with total body fat
(Figure 3E; Table S2a), consistent with previous reports [36]. More-
over, circulating FABP4 concentrations correlated significantly with468 MOLECULAR METABOLISM 3 (2014) 465e473  2014 Published by Elsevier GmbHGSIS (Figure 3F) supporting a role for FABP4 in coordinating the b-cell
response during obesity in humans. As adiposity may explain
increased GSIS per se, we performed linear regression with GSIS (AUC
or iAUC) as the dependent variable and serum FABP4 and fat mass (by
DXA) as the explanatory variables (Table S2b). Serum FABP4 explained
29.8% (AUC, P ¼ 0.017) and 27.7% (iAUC, P ¼ 0.021) of GSIS and. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Figure 2: FABP4 potentiates glucose-stimulated insulin secretion in vitro and in vivo. A, B, Isolated mouse islets were exposed to recombinant FABP4 (rFABP4) for 24 h, with or without the fatty acids
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presented as mean  SEM. *P < 0.05 by unpaired (A) or paired (E) t-test. P < 0.01 by 2-way ANOVA for treatment effect indicated in C. See also Figure S1.body fat was not retained in the model (P ¼ 0.711 and P ¼ 0.931 for
AUC and iAUC, respectively). Similar findings were obtained when BMI
replaced fat mass in the regression model (Table S2b). Overall, the
regression data suggest that FABP4 plays a major role in determining
GSIS in humans.MOLECULAR METABOLISM 3 (2014) 465e473  2014 Published by Elsevier GmbH. This is an open access ar
www.molecularmetabolism.com3.5. Insulin inhibits FABP4 secretion in vitro, in mice and in
humans
Most physiological endocrine systems exhibit feedback regulation. To
determine if the FABP4-insulin system also possesses feedback regu-
lationwe assessed the effect of insulin on FABP4 release fromadipocytes.ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Brief communicationCirculating FABP4 levels were rapidly suppressed by exogenous insulin
treatment, within 30 min in mice (Figure 4A) and 2 h in humans
(Figure 4B), and treatment of 3T3-L1 adipocytes with insulin potently
inhibited FABP4 release in vitro (Figure 4C). Conversely, insulin potenti-
ated adiponectin release under hypoxic conditions (Figure 4C), indicating
that the regulation of the release of these two hormones occurs via
distinct pathways. These data demonstrate that insulin provides rapid
feedback to regulate FABP4 release from adipocytes.
3.6. FABP4 secretion is regulated by b-3-adrenoreceptor signalling
As insulin signalling antagonises b-3 adrenergic signalling [44], we
sought to test the involvement of this pathway in FABP4 release.
Stimulation of adipocytes with b-3-adrenergic agonists induced a
robust increase in FABP4 secretion (Figure 4D) consistent with the
potent effect these compounds have on insulin secretion in vivo [45],
which is blunted by Fabp4 deletion [34]. To confirm this mode of
regulation, we next examined the role of cAMP since this is a major
conduit of b-3 adrenergic signalling. The cyclic-AMP elevating drug
IBMX markedly induced FABP4 release from adipocytes (Figure 4E). In
contrast, both b-3 adrenergic agonists and IBMX suppressed adipo-
nectin and complement C3 release (Figure 4D and E). These data
reveal that a cyclic-AMP activated pathway drives FABP4 release from
adipocytes independently of other adipokines.
4. DISCUSSION
Our study suggests that FABP4 may play a role in coordinating GSIS
with adiposity to maintain glucose homeostasis, thereby providing a
potentially parsimonious explanation for the development of enhanced
insulin secretion during obesity. In some respects this insulinotropic470 MOLECULAR METABOLISM 3 (2014) 465e473  2014 Published by Elsevier GmbHactivity resembles the actions of Glp1 [46], which is released from the
gut with feeding to acutely enhance insulin secretion. Hence, this
reinforces the notion that multiple organs, including the gut and adi-
pose tissue, play important roles in relaying peripheral metabolic
status to the b-cell, thereby enabling adjustments in secretory tone to
fulfil the appropriate output.
FABP4 has a plethora of roles in metabolic regulation. As one of the
most abundant proteins in the adipocyte it plays a crucial role in fatty
acid uptake, as well as promoting transcriptional activity in response to
specific ligands. Recently it has been shown to play a role in FA uptake
into muscle [38] and ovarian cancer cells [47], although the mecha-
nistic details of this are not clear. The important role of FABP4 and its
close homolog FABP5 in metabolism is underscored by the marked
alteration in tissue lipid profiles in Fabp4/Fabp5KO mice, which are
protected against diet-induced obesity and hyperglycaemia, and show
reduced insulin levels [39]. Moreover, the recent description of specific
roles for secreted FABP4 in potentiating hepatic glucose production
[37] and now insulin secretion, reinforces the role of this protein in
metabolic homeostasis. Despite the array of metabolic effects attrib-
uted to FABP4, its mode of action remains to be determined. One
feature that may consolidate many of these observations is the lipid
binding property of FABP4: nuclear localisation and transcriptional
activity in adipocytes are regulated by lipid binding [41,42]; liver
steatosis in Fabp4/Fabp5KO mice is attributed to a role for dysregu-
lated NEFA uptake into heart and skeletal muscle [38]; and we show
here in the case of the b-cell, that the most prominent effects of
rFABP4 on potentiating GSIS occur in the presence of linoleate.
Moreover, neither rFABP4 nor linoleate supplied alone at physiological
concentrations significantly altered GSIS. Therefore, the effect of
FABP4 and linoleate on b-cell function is likely due to synergistic. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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specific cellular location or pathway, or activation of a receptor by the
FABP4/linoleate complex, akin to the role of intracellular FABP4 in
activating adipocyte nuclear receptors [41].
Hypoxia modulates leptin expression [28,48] and secretion [48,49]
although, as 3T3L1 adipocytes do not express leptin, this adipokine
was absent from our conditioned media experiments and proteomic
screen. As leptin inhibits insulin secretion [14], this raises the question
as to whether leptin antagonises the effects of FABP4. However, as 1
week rFABP4 infusion enhanced glucose tolerance and GSIS in mice,
this suggests that FABP4 remains active in the presence of endoge-
nous adipokines (including leptin) in vivo. This is consistent with the
hyper-secretion of insulin in the presence of elevated leptin during
obesity.
We, and others [36,37], have observed increased circulating FABP4
levels in obese humans and mice. However, Fabp4 does not contain a
signal peptide, which would normally be required for targeting to the
secretory pathway, consistent with its presence in the cytosol ofMOLECULAR METABOLISM 3 (2014) 465e473  2014 Published by Elsevier GmbH. This is an open access ar
www.molecularmetabolism.comadipocytes. Despite this, we provide evidence that Fabp4 secretion
from the adipocyte is stimulated by hypoxia, b-adrenergic agonists or
cAMP, and regulated by insulin. Intriguingly, secretion of adiponectin
(which possesses a classical secretory signal peptide) was inversely
proportional to FABP4 release with these stimuli. In further support of
FABP4 secretion via a non-classical pathway, its regulated release
occurs via a golgi-independent (brefeldin A-insensitive) pathway in
adipocytes [37]. Taken together, these data suggest that FABP4 is
released from the adipocyte by a non-classical secretory pathway as
described for a range of growth factors and cytokines including FGF1,
FGF2, IL1a, IL1b and Y-box protein-1 [50,51]. An alternative possibility
is that FABP4 may be released as a function of adipocyte cell death, an
event that may be increased in frequency both with obesity and/or
hypoxia. We have found FABP4 to be highly expressed in the adipocyte
[23] and the demise of a relatively minor number of cells may generate
physiological levels of this protein in the systemic circulation. However,
our observations of rapid suppression of systemic FABP4 levels by
insulin, along with the relatively subtle increases in necrosis in ourticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Brief communicationconditioned media experiments, favours regulated secretion over cell
death as the mechanism of release. In addition, our results suggest
that adipocyte insulin resistance may impair insulin suppression of
FABP4 release, resulting in enhanced FABP4 secretion and increased
reciprocal insulin release, thereby compensating for insulin resistance
to maintain glucose and lipid homeostasis.
Our results reveal the therapeutic potential of targeting the FABP4-
insulin axis as a treatment for metabolic disease. Reinforcing or
enhancing FABP4 action on the b-cell may provide a novel incretin-like
therapy to enhance GSIS and improve glucose tolerance. Furthermore,
our observation that linoleate enhances the insulinotropic activity of
FABP4 provides a potential molecular mechanism that could be tar-
geted to modulate the action of circulating FABP4 on the b-cell.
Although our data support the notion that FABP4 is beneficial and
protects glucose homeostasis, it remains to be determined what the
long-term implications of up-regulating this mechanism may be.
Obesity predisposes individuals to diabetes, cardiovascular disease
and cancer, and chronic hyperinsulinaemia has been implicated in
exacerbating disease progression [52e54], suggesting that up-
regulation of circulating FABP4 levels may have both positive and
negative consequences. In conclusion, our study places circulating
FABP4 in a central role during obesity and related metabolic diseases.
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